Subscribe X
Back to Top

Learn

Archives

December 7, 2016 by Sandra Steingard, MD

Vermont Collaborative Network Approach Launched

vermont_b-nikkelI have had the great privilege and pleasure of working with a group of colleagues in Vermont who share my interest in bringing the humble and democratic ways of working developed in northern Finland and Norway to our state. Many of us were introduced to this work by Robert Whitaker’s description of Open Dialogue in Anatomy of an Epidemic and Daniel Mackler’s documentary Open Dialogue, and some of us worked with Tom Anderson, who came to Vermont in the 90s.

Some had traveled to Europe to attend the annual meeting of the International Network for the Treatment of Psychosis, the group of clinicians who had been working in this way for the past two decades. Others had the opportunity to train with Mary Olson, PhD at the Institute for Dialogic Practice. We have formed study groups and developed small teams who are beginning to introduce this way of working to our clinics.

Read More

November 22, 2016 by Sandra Steingard, MD

Moving ahead in troubled times

Sandra-SteingardThe Foundation for Excellence in Mental Health Care was founded in 2011 with the hope of expanding what many had come to believe was a narrow and faulty understanding of psychiatric conditions.

Read More

November 3, 2016 by IA Cristea et al | Br J Psychiatry

Sponsorship Bias in the Comparative Efficacy of Psychotherapy and Pharmacotherapy for Adult Depression: Meta-Analysis

BACKGROUND: Sponsorship bias has never been investigated for non-pharmacological treatments like psychotherapy.

AIMS: We examined industry funding and author financial conflict of interest (COI) in randomised controlled trials directly comparing psychotherapy and pharmacotherapy in depression.

METHOD: We conducted a meta-analysis with subgroup comparisons for industry v. non-industry-funded trials, and respectively for trial reports with author financial COI v. those without.

RESULTS: In total, 45 studies were included. In most analyses, pharmacotherapy consistently showed significant effectiveness over psychotherapy, g = -0.11 (95% CI -0.21 to -0.02) in industry-funded trials. Differences between industry and non-industry-funded trials were significant, a result only partly confirmed in sensitivity analyses. We identified five instances where authors of the original article had not reported financial COI.

CONCLUSIONS: Industry-funded trials for depression appear to subtly favour pharmacotherapy over psychotherapy. Disclosure of all financial ties with the pharmaceutical industry should be encouraged.

Get Full Text: Journal site

 

© The Royal College of Psychiatrists 2017.

PubMed: 27810891

DOI: 10.1192/bjp.bp.115.179275

 

Source: https://www.ncbi.nlm.nih.gov/labs/articles/27810891/

Read More

March 31, 2016 by Brian Farr, MA, LPC

Celebrating Six Months at EXCELLENCE

Brian-FarrOn March 14th, I celebrated six months in my new position as Director of Philanthropy at EXCELLENCE. Why did I choose to work at EXCELLENCE and not somewhere else? I believe in the mission. I believe that five years from now, because of this organization, the mental health care delivery system in the United States will be more compassionate and more effective than it is today.

Read More

November 13, 2015 by EXCELLENCE Editor

“Psychiatric Drugs Do More Harm Than Good”

Copenhagen, September 16, 2015 Conference Video Series

Peter Gøtzsche of the Cochrane Centre in Copenhagen arranged this conference uncovering what the scientific literature reveals about the effects of psychiatric medication. Those lectures are followed by real world accounts.

Part 1 with Robert Whitaker: Our Psychiatric Epidemic – A Historical Overview.

Read More

April 21, 2015 by BMJ Editorial | David Healy, MD

Serotonin and depression: The marketing of a myth

David-HealyThe serotonin reuptake inhibiting (SSRI) group of drugs came on stream in the late 1980s, nearly two decades after first being mooted. The delay centred on finding an indication. They did not have hoped for lucrative antihypertensive or antiobesity profiles. A 1960s idea that serotonin concentrations might be lowered in depression1 had been rejected,2 and in clinical trials the SSRIs lost out to the older tricyclic antidepressants as a treatment for severe depression (melancholia).3,4,5

When concerns emerged about tranquilliser dependence in the early 1980s, an attempt was made to supplant benzodiazepines with a serotonergic drug, buspirone, marketed as a non-dependence producing anxiolytic. This flopped.6 The lessons seemed to be that patients expected tranquillisers to have an immediate effect and doctors expected them to produce dependence. It was not possible to detoxify the tranquilliser brand.

Instead, drug companies marketed SSRIs for depression, even though they were weaker than older tricyclic antidepressants, and sold the idea that depression was the deeper illness behind the superficial manifestations of anxiety. The approach was an astonishing success, central to which was the notion that SSRIs restored serotonin levels to normal, a notion that later transmuted into the idea that they remedied a chemical imbalance. The tricyclics did not have a comparable narrative.

Read More

November 17, 2014 by Peter Kinderman | Scientific American

Why We Need to Abandon the Disease-Model of Mental Health Care

The idea that our more distressing emotions such as grief and anger can best be understood as symptoms of physical illnesses is pervasive and seductive.

The idea that our more distressing emotions such as grief and anger can best be understood as symptoms of physical illnesses is pervasive and seductive. But in my view it is also a myth, and a harmful one. Our present approach to helping vulnerable people in acute emotional distress is severely hampered by old-fashioned, inhumane and fundamentally unscientific ideas about the nature and origins of mental health problems. We need wholesale and radical change, not only in how we understand mental health problems, but also in how we design and commission mental health services.

Read More


Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
    READ BLOG
  • ISEPP Chronicles

    ISEPP Chronicles

    The International Society for Ethical & Psychiatry blog.
    READ BLOG
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
    READ BLOG
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
    READ BLOG
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
    READ BLOG
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
    READ BLOG
  • 1boringoldman

    1boringoldman

    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.
    READ BLOG